Differential expression of anterior gradient gene AGR2 in prostate cancer by Maresh, Erin L et al.
RESEARCH ARTICLE Open Access
Differential expression of anterior gradient gene
AGR2 in prostate cancer
Erin L Maresh
1, Vei Mah
1, Mohammad Alavi
1, Steve Horvath
2,3, Lora Bagryanova, Emily S Liebeskind
4,5,
Laura A Knutzen
6, Yong Zhou
6, David Chia
1,7, Alvin Y Liu
4,5, Lee Goodglick
1,7*
Abstract
Background: The protein AGR2 is a putative member of the protein disulfide isomerase family and was first
identified as a homolog of the Xenopus laevis gene XAG-2. AGR2 has been implicated in a number of human
cancers. In particular, AGR2 has previously been found to be one of several genes that encode secreted proteins
showing increased expression in prostate cancer cells compared to normal prostatic epithelium.
Methods: Gene expression levels of AGR2 were examined in prostate cancer cells by microarray analysis. We
further examined the relationship of AGR2 protein expression to histopathology and prostate cancer outcome on a
population basis using tissue microarray technology.
Results: At the RNA and protein level, there was an increase in AGR2 expression in adenocarcinoma of the
prostate compared to morphologically normal prostatic glandular epithelium. Using a tissue microarray, this
enhanced AGR2 expression was seen as early as premalignant PIN lesions. Interestingly, within adenocarcinoma
samples, there was a slight trend toward lower levels of AGR2 with increasing Gleason score. Consistent with this,
relatively lower levels of AGR2 were highly predictive of disease recurrence in patients who had originally
presented with high-stage primary prostate cancer (P = 0.009).
Conclusions: We have shown for the first time that despite an increase in AGR2 expression in prostate cancer
compared to non-malignant cells, relatively lower levels of AGR2 are highly predictive of disease recurrence
following radical prostatectomy.
Background
It is estimated that in 2010, there will be over 217,000
new cases of prostate cancer and over 32,000 deaths
from this disease in the United States alone, making it
the most common male cancer and the second leading
cause of cancer-related deaths in men [1]. Prostate can-
cer is generally diagnosed by serum level of prostate-
specific antigen (PSA) and digital rectal exam. However,
although PSA is abundantly synthesized by the prostate,
it is not cancer specific, leading to many unnecessary
biopsies. Improved markers for both identifying prostate
cancer and predicting its outcome are needed. Our
approach to discover such markers involved comparative
analysis of the transcriptomes of cancer cells and
normal cells. These transcriptomes were determined
through sorting of specific cell types from appropriate
tissue specimens for analysis by Affymetrix DNA micro-
arrays [2]. Genes that were found overexpressed by 8-
fold or more in cancer cells were biomarker candidates,
especially those that encode secreted or extracellular
proteins. The coding sequences were analyzed with Sig-
nalP 2.0 [3] for signal peptides and TMHMM [4] for
protein topology and the number of transmembrane
helices. AGR2 (anterior gradient 2) was one among sev-
eral such genes identified as overexpressed in prostate
cancer cells. The array signal level for AGR2 in the can-
cer cells was ~50-fold higher than that in luminal cells,
the normal counterpart [5].
AGR2 is the human homolog of the protein XAG-2 in
Xenopus laevis and was first identified as differentially
expressed in estrogen receptor positive breast cancer
cell lines [6]. Biochemically, AGR2 is classified as a
member of the protein disulfide isomerase (PDI) family
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enzymes in the endoplasmic reticulum act as molecular
chaperones for protein folding. As such, AGR2 is
thought to act as a chaperone to clear misfolded pro-
teins out of cells during periods of physiological stress
[8]. Studies have found that AGR2 expression can be
increased in response to physiological stress in breast
cancer cells and can enhance survival of damaged lung
cancer cells [8,9]. PDI enzymes are found in other sub-
cellular compartments and are thought to participate in
or modulate a range of functions, from cell adhesion to
DNA binding [10-12].
Several cancers, including breast [13-16], prostate
[17-21], fibrolamellar [22], pancreatic [23-25], and colon
[26], have been found to express increased levels of
AGR2 compared to normal tissue. Furthermore, AGR2
has been shown to increase tumor cell migration
in vitro and the incidence of metastatic lesions in vivo
[15,18,21,27]. Accordingly, some studies have found
AGR2 to be a marker of poor prognosis in human
breast and prostate cancers [14,19,28,29]. One the other
hand, some studies have found AGR2 to show no asso-
ciation with patient outcome in lung and pancreatic
cancer [23,30] or even improved outcome in breast can-
cer [13].
To further evaluate the utility of AGR2 as a cancer
biomarker, we examined the expression pattern of
AGR2 in prostate cancer using both gene expression
analysis and a high-density tissue microarray.
Methods
Gene expression analysis of AGR2 in prostate cancer
Two publically available datasets were used to examine
AGR2 gene expression in human prostate samples
[31,32]. The first dataset was generated using Affymetrix
U95B Array (GEO Accession number GDS2546) [31]. It
included 66 prostate cancer tissues, 17 normal prostate
tissues, and 25 metastatic prostate tumor samples
obtained from 4 patients. The second data set was gen-
erated using a cDNA microarray from the Stanford
Microarray Database (GEO Accession number
GSE3933) [32]. The dataset included 62 primary tumor
tissues, 41 matched normal prostate tissues, and 9
unmatched pelvic lymph node metastases. For all data-
sets we used the peer-reviewed normalization proce-
dures described by the authors. We downloaded the
normalized data from the GEO database.
Prostate tissue microarray analysis
Formalin-fixed, paraffin-embedded archival tumor speci-
mens were obtained from 187 patients who underwent
radical retropubic prostatectomy between 1984 and
1995 at the UCLA Medical Center. The construction of
the prostate tissue microarray (TMA) and the utilization
of the TMA were performed under appropriate UCLA
IRB approval. Case material was reviewed for TMA con-
struction by a study pathologist. At least three core tis-
sue biopsies 0.6 mm in diameter were taken from
morphologically representative regions of each prostate
tumor and arrayed as previously described [33-35].
Matched benign (morphologically normal or benign pro-
static hyperplasia/BPH) and in situ lesions of prostatic
intraepithelial neoplasia (PIN) were also included. The
prostate TMA was evaluated for AGR2 expression using
a standard immunohistochemistry protocol as previously
described [33-36]. Briefly, 4 micron sections were cut
from each array block. Following deparaffinization and
antigen retrieval, endogenous peroxidases were
quenched and tissue was blocked with goat serum.
Slides were incubated with rabbit polyclonal anti-AGR2
antibody at 1:400 (NB110-17780, Novus Biologicals, Lit-
tleton, CO) overnight at 4°C. Specific staining was
detected by applying goat anti-rabbit horseradish peroxi-
dase-conjugated secondary antibody and avidin-biotin
complex followed by diaminobenzidine (Vector ABC,
Burlingame, CA). If a tissue was positive for expression,
only glandular epithelium stained. Moreover, the anti-
AGR2 staining showed a dose-dependent titration of
signal. Human colonic epithelium was used as a positive
control for antibody staining. For negative control, tissue
was incubated with concentration-matched non-immune
rabbit IgG. Negative controls demonstrated no staining.
Staining frequency and intensity of AGR2 expression
on the TMA was assessed by our pathologist (M.A.) and
spot-checked by a second pathologist (V.M.) as
described previously [34,36]. The correlation coefficient
between scores from the two pathologists was r = 0.95.
The percentage of glandular cells staining was scored
from 0-100% and the intensity of staining was rated
from 0 for below the level of detection to 3 for strong
expression. An integrated measure of expression for fre-
quency and intensity of staining was calculated using
the following formula: [3(%x)+2(%y)+1(%z)]/100, where
x, y, and z represented the percentage of cells staining
at intensity 3, 2, and 1, respectively. For outcomes analy-
sis, a mean pooled value for each case was determined
as described previously [34-37].
Statistical analysis
Statistical analyses were conducted as previously
reported [34,36-38]. Briefly, non-parametric two-group
and multi-group comparisons were carried out using
Mann-Whitney and Kruskal-Wallis tests. Correlations
were calculated using Spearman correlations. Patients
were dichotomized at the 75
th percentile of AGR2
expression, and survival curves were visualized using the
Kaplan-Meier plot with the difference between survival
distributions assessed by the log-rank test. The Cox
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cal significance of predictors in both a univariate and a
multivariate setting. All statistical analyses were per-
formed with StatView Version 5.0 (SAS Institute, Cary,
NC) or with the freely available software package R
http://www.r-project.org.
Results
AGR2 mRNA expression in human prostate tissue
Several malignancies have been shown to express
increased levels of AGR2 compared to non-malignant
tissue. To further evaluate the utility of AGR2 as a can-
cer biomarker, we examined the gene expression pattern
of AGR2 in human prostate cancer compared to non-
malignant prostatic glandular epithelium. To do this we
analyzed AGR2 expression from two large publically
available datasets from the GEO database from which
normalized results were available [31,32]. Figure 1A and
1B show mean relative expression values for each data-
set. In both populations, AGR2 transcript levels were
significantly higher in primary prostate cancer tissue
compared to non-malignant prostate. Interestingly, tran-
script levels of AGR2 in metastatic lesions were also
lower than the associated primary tumor (Figure 1A and
1B).
Differential AGR2 expression in prostate cancer tissue
We further considered AGR2 protein expression in a
patient cohort using a prostate TMA. The TMA con-
sisted of specimens from 226 cases, of which 187 were
informative. Cases were uninformative if their tissue
spots contained no relevant epithelial cells (i.e., tumor
or benign), if spots were physically missing, or if, for
outcomes data, there was no information on disease
recurrence. The characteristics of the patients on the
TMA are listed in Table 1. AGR2, if present, was predo-
minantly expressed in the cytoplasm of epithelial cells
(Figure 2). When we examined AGR2 expression for
each array spot, the level of AGR2 expression was
increased in PIN lesions as well as adenocarcinoma
compared to BPH and morphologically normal adjacent
tissue (P 3). This was consistent with the cancer-specific
expression of AGR2 shown in Figure 1. Representative
images of weak, moderate, or strong AGR2 expression
are shown in Figure 2. Overall, regional metastases
tended to show AGR2 expression higher than BPH and
normal tissue (P = 0.027 and P = 0.030, respectively;
Figure 3). Moreover, there was an increase in AGR2
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Figure 1 AGR2 transcript expression in prostate cancer.T w o
publically available datasets were used to examine AGR2 gene
expression in human prostate samples [31,32]. (A) Dataset was from
Yu, et al., and was generated using Affymetrix U95B Array [31]. (B)
Dataset was from Lapointe, et al., and was generated using a cDNA
microarray from the Stanford Microarray Database [32]. For each
dataset, normalized data was available from the GEO database. The
bars are the relative mean expression value ± standard error of the
mean. P < 0.0001 for each multi group comparison (Kruskal-Wallis).
Table 1 Clinicopathologic parameters and AGR2
expression in patients with prostate cancer
All
patients
Mean AGR2 expression
(SE)
P-
value
Total cases 187 0.548 (0.040)
Age at surgery 0.929
2
Median
(range)
65 (46-76)
Mean 63.7
Gleason score 0.986
1
2-6 107 0.544 (0.052)
7-10 80 0.553 (0.064)
Stage
I/II 122 0.559 (0.054) 0.764
1
III/IV 65 0.527 (0.057)
pT stage 0.767
1
pT2-pT3a 152 0.560 (0.047)
pT3b 35 0.495 (0.076)
Lymph node
status
0.180
1
Positive 11 0.353 (0.118)
Negative 174 0.564 (0.043)
Tumor margins 0.347
1
Positive 64 0.490 (0.060)
Negative 123 0.578 (0.053)
Capsular invasion 0.484
1
No invasion 43 0.573 (0.107)
Invasion 144 0.540 (0.042)
Organ confined 0.477
1
Yes 93 0.598 (0.066)
No 94 0.498 (0.047)
PSA ng/mL 0.339
2
Median
(range)
9.6 (0.6-
96.5)
0.413
1
Mean 14.0
< 10 88 0.509 (0.057)
≥10 79 0.563 (0.064)
1Mann-Whitney,
2Spearman Correlation. Cases that were uninformative for a
given variable were removed from the statistical analysis.
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Page 3 of 8expression in Gleason grades 3 and 4 compared to 2 (P
< 0.0001 and P = 0.0007; Figure 4). There was a signifi-
cant drop in expression in grade 5 tumors compared to
grades 3 and 4 (P = 0.0028 and P = 0.0085; Figure 4).
Decreased AGR2 expression in high-stage prostate cancer
predicts greater probability of recurrence
The differential AGR2 expression in prostate cancer
prompted us to examine possible links between expres-
sion and clinical outcomes. The outcomes measure we
considered was tumor recurrence following radical pros-
tatectomy as diagnosed by measurable blood PSA.
AGR2 expression was not predictive of tumor recur-
rence either as a continuous or dichotomized variable
(P = 0.596 and P = 0.281, Table 2). Patients were also
grouped into high stage (III and IV) versus low stage
(I and II) subpopulations. AGR2 provided no predictive
value for recurrence for individuals with low stage can-
cer. In contrast, AGR2 was a strong predictor of tumor
recurrence for individuals with high stage prostate can-
cer (Figure 5). Specifically, relatively lower levels of
AGR2 predicted a significantly greater chance of pros-
tate cancer recurrence compared to higher levels (P =
0.009). The median recurrence-free time in the lower
AGR2 group was 14 months compared to 38.5 months
in the group with relatively higher AGR2 expression.
Although AGR2 expression was associated with longer
time to recurrence in higher stage cancers, AGR2 did not
significantly associate with any other clinicopathological
variables in this subgroup, such as Gleason score, lymph
node status, tumor margins, or PSA levels (Table 3). To
see whether AGR2 was an independent predictor of sur-
vival, we used a multivariate Cox model including dichot-
omized AGR2 expression, Gleason sum, PSA levels, and
Figure 2 AGR2 immunohistochemistry.A G R 2s t a i n i n gw a s
localized to the cytoplasm and membrane of cancer epithelial cells.
(A) Tissue samples incubated with concentration-matched non-
immune rabbit IgG showed no staining. Shown are representative
sections of (B) morphologically normal tissue, (C) PIN, and (D) a
representative adenocarcinoma (Gleason grade 7) showing low
staining intensity, (E) a representative adenocarcinoma (Gleason
grade 8) showing moderate staining intensity, and (F) a
representative adenocarcinoma (Gleason grade 6) showing high
staining intensity.
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Figure 3 AGR2 expression by spot level histopathology.T h e
barplots show the mean integrated AGR2 expression by TMA spot-
level histology in morphologically normal (NL), BPH, PIN,
adenocarcinoma (AD), and lymph node metastases (LNMET); bars
are standard errors. Levels of AGR2 expression were increased in PIN
lesions and adenocarcinoma compared to BPH and morphologically
normal adjacent tissue (P < 0.0001). Regional metastases showed
increased AGR2 expression compared to BPH and normal tissue (P
= 0.027 and P = 0.030, respectively).
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Figure 4 AGR2 expression by spot level Gleason grade.T h e
barplots show the mean integrated AGR2 expression by TMA spot-
level Gleason grade; bars are standard errors. Average AGR2
expression was increased in grades 3 and 4 compared to grade 2 (P
< 0.0001 and P = 0.0007) and grade 5 (P = 0.0028 and P = 0.0085).
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sion showed a trend toward significance (P = 0.087).
Discussion
AGR2 has been implicated in cancer pathogenesis and
has been found to be up-regulated in multiple human
cancers, including breast, lung, and prostate
[13,14,18-20,30]. Our study has shown that AGR2 is
higher in prostate cancer cells compared to non-malig-
nant prostatic epithelial cells at the transcript and pro-
tein levels. This is consistent with other recent studies
which have found an increase in AGR2 mRNA using
microarray analysis of laser-capture microdissected cells
and an increase in AGR2 protein levels [17-21,39,40].
Using TMA technology, we also verify a greatly
e n h a n c e dA G R 2p r o t e i ne x p r e s s i o ni nm a l i g n a n ta n d
early malignant PIN lesions compared to non-malignant
epithelium. We observed that AGR2 levels were lower
in advanced disease states as Gleason grade 5 spots
expressed dramatically less AGR2 than grade 4 and
grade 3 spots. Finally, we showed, for the first time, a
novel predictive value for AGR2 expression with regard
to tumor recurrence in individuals with higher stage dis-
ease. In this situation, relatively lower levels of AGR2
expression predicted a higher likelihood of tumor
recurrence.
The exact biological role of AGR2 in humans is lar-
gely unknown. The AGR2 homolog in X. laevis,X A G 2 ,
has 73% similarity and 47% identity at the protein level
[6] and plays a role in the differentiation of the mucus-
secreting cement gland found on the anterior aspect of
the frog embryo [41]. The newt homolog, nAG, has
been shown to induce cellular proliferation in dener-
vated limbs [42]. In the adult, AGR2 expression is
restricted to a limited number of tissues and cell types
in the body suggesting it is not a ubiquitously expressed
product [43]. In the intestine, for example, AGR2 is
found in the goblet cells and appears necessary for the
production of intestinal mucus [44,45]. In malignant
cells from organs such as the breast and prostate, AGR2
may be involved in additional functions. Interestingly, in
various models of tumor progression, increased AGR2
promotes cell migration, invasion, and presumably
metastatic spread [15,18,21,27,28,46,47]. However, the
story may be more complicated as recently Bu, et al.
observed that while over-expressed AGR2 in prostate
cancer cells increased migration and invasion, it addi-
tionally repressed growth and proliferation [21]. The
exact mechanistic role for AGR2 in these functions
remains to be elucidated.
In our data, the lower expression of AGR2 in higher
Gleason tumors appears to correlate with AGR2 being
predictive of prostate cancer recurrence in individuals
with higher stage cancers. Many studies report that
AGR2 expression corresponds to a more differentiated
phenotype [13,30,46]. Lower Gleason scores are indica-
tive of well-differentiated tumors. If AGR2 indeed has
opposing functions of promoting migration and invasion
with higher expression yet allowing/promoting cellular
proliferation upon decreased expression [21], it is intri-
guing to consider that our results reflect this balance of
0
0.2
0.4
0.6
0.8
1.0
R
e
c
u
r
r
e
n
c
e
-
f
r
e
e
 
p
r
o
b
a
b
i
l
i
t
y
0 20 40 60 80 100 120 140
Time to recurrence (months)
Low AGR2 expression (n = 44)
High AGR2 expression (n = 21)
Figure 5 AGR2 levels predict prostate cancer recurrence in
high stage patients. Solid line is relatively higher AGR2 levels
(staining measure ≥0.79); dashed line is relatively lower AGR2 levels
(< 0.79). In men with stage III or IV prostate cancer, relatively lower
levels of AGR2 predict a significantly greater chance of prostate
cancer recurrence compared to those with higher levels (P = 0.009).
Table 2 Univariate Cox model
All Patients (n = 187) Stage III/IV Patients (n = 65)
Variable HR 95% CI P-Value HR 95% CI P-Value
AGR2 continuous 0.89 0.57 - 1.38 0.596 0.50 0.24 - 1.04 0.062
AGR2 dichotomized 0.75 0.44 - 1.27 0.281 0.37 0.17 - 0.81 0.013
Gleason sum
1 3.78 2.26 - 6.33 < 0.0001 1.88 0.90 - 3.93 0.093
Preoperative PSA 1.02 1.00 - 1.03 0.011 1.00 0.98 - 1.02 0.884
pT stage
2 3.89 2.36 - 6.40 < 0.0001 2.63 1.26 - 5.49 0.010
1Gleason sum was dichotomized as low (< 7) vs. high (7-10).
2 pT stage was dichotomized as pT2-pT3a vs. pT3b.
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later stage prostate cancer, the balance towards
increased proliferation (e.g., lower AGR2 expression)
outweighs the need for enhanced migration and invasion
(e.g., higher AGR2 expression). We are currently testing
this hypothesis both in vitro and in vivo.O fi n t e r e s t
Zhang et al., also used TMA technology to examine the
associate of AGR2 expression levels with prostate cancer
outcome [19]. Similar to us, they observed an increase
in AGR2 expression in prostate cancer compared to
normal or benign tissue. However, in apparent contrast
to our results, they observed that increased AGR2 was
associated with a poorer outcome [19]. While the expla-
nation for this apparent discrepancy is unclear, it should
be noted that Zhang et al. considered overall survival
while our outcome measure was disease-specific recur-
rence. We did not have sufficient numbers of patients in
our cohort who died from the disease in order to con-
duct meaningful statistical analysis of survival. Whether
or not other subtle differences in treatment, clinical his-
tory, and/or demographics existed in the patient cohort
at UCLA versus the Royal Liverpool University Hospital
is difficult to assess. Nevertheless, whether the prognos-
t i cs i g n i f i c a n c eo fA G R 2v a r i e sb a s e do nt h eo u t c o m e
Table 3 Clinicopathologic parameters and AGR2 expression in patients with high stage prostate cancer
Stage III/IV patients Mean AGR2
expression (SE)
P-value Low AGR2 High AGR2 P-value
Total cases 65 0.53 (0.057) 44 21
Age at surgery 0.762
2 0.763
1
Median (range) 66 (50-76) 66 (50-76) 65 (50-73)
Mean 64.6 64.8 64.3
Gleason score 0.098
1 0.161
3
2-6 22 0.664 (0.104) 12 10
7-10 43 0.457 (0.066) 32 11
pT stage 0.451
1 0.111
3
pT2-pT3a 30 0.565 (0.087) 17 13
pT3b 35 0.495 (0.076) 27 8
Lymph node status 0.118
1 0.480
3
Positive 11 0.353 (0.118) 9 2
Negative 54 0.563 (0.064) 35 19
Tumor margins 0.990
1 0.794
3
Positive 35 0.536 (0.087) 23 12
Negative 30 0.517 (0.072) 21 9
Capsular invasion 0.805
1 > 0.999
3
No invasion 4 0.507 (0.174) 3 1
Invasion 61 0.529 (0.060) 41 20
PSA ng/mL 0.414
2 0.089
1
Median (range) 11.9 (2.1-96.5) 0.353
1 0.092
3
Mean 18.7
< 10 25 0.607 (0.103) 14 11
≥10 32 0.463 (0.073) 25 7
1Mann-Whitney,
2Spearman Correlation,
3Fisher’s Exact Test. Cases that were uninformative for a given variable were removed from the statistical analysis.
Table 4 Multivariate Cox model
All Patients (n = 165)
2 Stage III/IV Patients (n = 57)
3
Variable HR 95% CI P-Value HR 95% CI P-Value
AGR2 dichotomized 0.83 0.46 - 1.52 0.549 0.44 0.17 - 1.13 0.087
Gleason sum
1 3.18 1.67 - 6.08 0.0005 1.14 0.42 - 3.07 0.795
Preoperative PSA 1.00 0.98 - 1.01 0.713 0.99 0.97 - 1.01 0.440
pT stage
2 2.39 1.28 - 4.47 0.0064 2.57 1.00 - 6.65 0.051
1Gleason sum was dichotomized as low (< 7) vs. high (7-10).
2 pT stage was dichotomized as pT2-pT3a vs. pT3b.
3 In all patients, 165 of 187 cases were informative for all four variables.
4 In stage III/IV patients, 57 of 65 cases were informative for all four variables.
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warrants further investigation.
Our group, as well as others, is also examining AGR2
as a potential prostate cancer biomarker. In this regard,
AGR2 has the following interesting attributes. First, it
appears to be expressed at relatively high levels in indi-
viduals with prostate cancer;e x p r e s s i o ni sl o w e rf r o m
normal or non-malignant prostatic epithelium. Second,
since AGR2 is secreted, there is the likelihood that the
protein can be detected in blood or urine. Indeed Bu
et al., have detected increased AGR2 transcript in urine
sediments from prostate cancer patients [21]. That
AGR2 is secreted is supported by our results as well as
by mass spectrometry proteomic analysis of 2-D gel
electrophoresis spots reported in the literature [48]. We
are currently exploring whether AGR2 detected in body
fluids is an accurate gauge for prostate cancer initiation,
progression, and/or outcome. In particular, we are
developing an assay to detect subnanogram per ml levels
of AGR2. New monoclonal AGR2 antibodies need to be
produced, however, since we found that the commer-
cially available one did not recognize native AGR2 in
solution.
Conclusions
In summary, we found that AGR2 is a secreted protein
expressed at relatively high levels by prostate cancer
cells and cells in PIN lesions. We found that a relatively
higher expression of AGR2 in patients with high stage
prostate cancer stratified thes ei n d i v i d u a l sa sl e s sl i k e l y
to have a tumor recurrence.
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